Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
Dong-Sung Kim, Lorenz Herdeis, Dorothea Rudolph, et al.
Nature (2023) Vol. 619, Iss. 7968, pp. 160-166
Open Access | Times Cited: 253

Showing 1-25 of 253 citing articles:

Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 155
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 994-1017
Open Access | Times Cited: 74
Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 927-936
Open Access | Times Cited: 55
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Alex Friedlaender, M. Pérol, Giuseppe Luigi Banna, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 36
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D
Qinheng Zheng, Ziyang Zhang, Keelan Z. Guiley, et al.
Nature Chemical Biology (2024) Vol. 20, Iss. 9, pp. 1114-1122
Open Access | Times Cited: 32
Targeting cancer with small-molecule pan-KRAS degraders
Johannes Popow, William Farnaby, Andreas Gollner, et al.
Science (2024) Vol. 385, Iss. 6715, pp. 1338-1347
Open Access | Times Cited: 31
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Jeffrey A. Klomp, Jennifer E. Klomp, Clint A. Stalnecker, et al.
Science (2024) Vol. 384, Iss. 6700
Open Access | Times Cited: 30
Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death
Chi Zhou, Wenxin Li, Liang Zhenxing, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 27
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 22
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies
Melody Riaud, Jennifer Maxwell, Isabel Soria‐Bretones, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 2, pp. 105-122
Closed Access | Times Cited: 21
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers
Douglas A. Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, et al.
Cancer Discovery (2024) Vol. 14, Iss. 5, pp. 727-736
Open Access | Times Cited: 16
KRAS G12C inhibitor combination therapies: current evidence and challenge
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Daoyan Wei, Liang Wang, Xiangsheng Zuo, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 4, pp. 655-662
Open Access | Times Cited: 35
Simultaneous Covalent Modification of K-Ras(G12D) and K-Ras(G12C) with Tunable Oxirane Electrophiles
Zhongtang Yu, Xiaoqiang He, R. Wang, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 37, pp. 20403-20411
Closed Access | Times Cited: 25
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Firas Batrash, Mahmoud Kutmah, Jun Zhang
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 22
Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets
Edward W. Tate, Lior Soday, Ana Losada de la Lastra, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 4, pp. 240-260
Closed Access | Times Cited: 14
Recent advances in drug delivery and targeting for the treatment of pancreatic cancer
Nilkamal Pramanik, Aditya K. Gupta, Yashwardhan Ghanwatkar, et al.
Journal of Controlled Release (2024) Vol. 366, pp. 231-260
Closed Access | Times Cited: 13
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Anna Linehan, Mary O’Reilly, Ray McDermott, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 13
Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins
Alexander Chan, Rebecca M. Haley, Mohd Altaf Najar, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Hippo Signaling at the Hallmarks of Cancer and Drug Resistance
Ramesh Kumar, Wanjin Hong
Cells (2024) Vol. 13, Iss. 7, pp. 564-564
Open Access | Times Cited: 12
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Marie‐Julie Nokin, Alessia Mira, Enrico Patrucco, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top